Skip to main content

Table 1 IC50s of sorafenib and metapristone on HCC cell lines in vitro. Data are expressed as the mean ± SD (n = 3)

From: Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib

HCC cell lines

IC50 (μM)

Sorafenib

Metapristone

24H

48H

24H

48H

SMMC-7721

21.87 ± 5.27

10.06 ± 3.69

120.30 ± 21.07

47.24 ± 8.44

HepG2

10.46 ± 2.69

5.93 ± 2.25

118.49 ± 15.28

62.23 ± 9.81

Huh7

13.14 ± 0.63

10.91 ± 0.69

106.06 ± 10.27

69.27 ± 4.55

Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us